In The Lancet today, Keertan Dheda and co-authors present an interesting report about early treatment outcomes of extensively drug-resistant (XDR) tuberculosis (resistant to isoniazid, rifampicin, any fluoroquinolone, and at least one injectable drug: capreomycin, kanamycin, or amikacin) in South Africa. Culture conversion and mortality, stratified by HIV status, were retrospectively reviewed from the original records of a large cohort of 174 cases diagnosed between 2002 and 2008.

Read more The Lancet, 19 May 2010
Download article